Effect of lactic acid suppositories compared with oral metronidazole and placebo in bacterial vaginosis: a randomised clinical trial.
OBJECTIVE
To compare the effect of lactic acid locally, metronidazole orally and placebo in women with bacterial vaginosis.


METHODS
Randomised clinical trial.


METHODS
30 general practices in the Netherlands.


METHODS
125 women consulting the general practitioner for symptomatic bacterial vaginosis.


METHODS
Duration of subjective symptoms, recurrence of symptoms, clinically diagnosed cure, adverse events.


RESULTS
Survival analysis showed a significantly faster disappearance of symptoms in the metronidazole category compared with both lactic acid and placebo (p = 0.0005 metronidazole v placebo, p = 0.0002 metronidazole v lactic acid p = 0.6521 lactic acid v placebo [The stratified Mantel Cox test]). The median duration until absence of symptoms was 21 days for metronidazole and 80 days for placebo. Disappearance of symptoms did not occur in 50% of the lactic acid group in 90 days. Recurrence rates of symptoms were similar over the treatment categories (p = 0.13 metronidazole v placebo and p = 0.12 lactic acid v placebo). After 2 weeks cure rates (cure defined as less than three of four clinical criteria present) were 83%, 49% and 47% for metronidazole, lactic acid and placebo category respectively. At that time cure rates (cure defined as none of three clinical criteria present) were 10%, 0% and 3%. After four weeks and three months these figures were: 55%, 20%, 20% and 64%, 28%, 28%. No differences in adverse events were found between the three interventions.


CONCLUSIONS
Lactic acid suppositories are ineffective, metronidazole capsules are effective on signs and symptoms in bacterial vaginosis. A considerable proportion of the patients recover without active medication.
Boeke
A J
AJ
Department of General Practice, Faculty of Medicine, Vrije Universiteit, Amsterdam, Netherlands.
Dekker
J H
JH
van Eijk
J T
JT
Kostense
P J
PJ
Bezemer
P D
PD
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D007773:Lactates / Q000008:administration & dosage*; D008795:Metronidazole / Q000008:administration & dosage*; D008875:Middle Aged; D012008:Recurrence; D013488:Suppositories; D013997:Time Factors; D016585:Vaginosis, Bacterial / Q000188:drug therapy*
D007773:Lactates; D013488:Suppositories; D008795:Metronidazole